[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574188":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":157,"collaborators":19,"id":159,"slug":160,"hasResults":161,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":19,"eligibilityCriteria":165,"healthyVolunteers":161,"sex":166,"minAge":167,"maxAge":19,"enrollmentInfo":168,"targetDuration":19,"studyType":171,"phases":172,"briefSummary":174,"conditions":175,"keywords":187,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":201},{"fullName":5,"class":6},"Context Therapeutics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CT-95","EXPERIMENTAL","Phase 1a: Dose Escalation - each dose cohort will assess toxicity 28 days following the first dose of CT95 anticipate a total of 8 dose cohorts.\n\nPhase 1b: Dose Expansion - approximately 80 participants will be evaluated in 2-4 indication-specific expansion cohorts.",[13],"Drug: CT-95",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","MSLN bispecific antibody to be administered according to the dose and schedule of the assigned cohort until documentation of disease progression (or confirmed disease progression), unacceptable toxicity, or participant\u002Fphysician decision.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Karen Chagin, MD","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Context Clinical Development","CONTACT","267-225-7416","cntx-ct95-101@contexttherapeutics.com",[31,50,64,78,92,107,117,130,144],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Context Investigational Site","RECRUITING","Denver","Colorado","80218","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-104.9847,39.73915,{"lat":43,"lon":42},[46],{"name":47,"role":27,"phone":48,"phoneExt":19,"email":49},"Front Desk","720-754-2610","CANN.DDUDenverGeneral@SarahCannon.com",{"facility":32,"status":33,"city":51,"state":52,"zip":53,"country":37,"countryCode":38,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Chicago","Illinois","60637",{"type":40,"coordinates":55},[56,57],-87.65005,41.85003,{"lat":57,"lon":56},[60],{"name":61,"role":27,"phone":62,"phoneExt":19,"email":63},"Cancer Clinical Trials","773-702-6233","Cancerclinicaltrials@bsd.uchicago.edu",{"facility":32,"status":33,"city":65,"state":66,"zip":67,"country":37,"countryCode":38,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Grand Rapids","Michigan","49546",{"type":40,"coordinates":69},[70,71],-85.66809,42.96336,{"lat":71,"lon":70},[74],{"name":75,"role":27,"phone":76,"phoneExt":19,"email":77},"Ashley Spagnuolo","616-954-5552","ashley.spagnuolo@startresearch.com",{"facility":32,"status":33,"city":79,"state":80,"zip":81,"country":37,"countryCode":38,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Hackensack","New Jersey","07601",{"type":40,"coordinates":83},[84,85],-74.04347,40.88593,{"lat":85,"lon":84},[88],{"name":89,"role":27,"phone":90,"phoneExt":19,"email":91},"Oncology Clinical Research Referral Office","551-996-1777","OncologyResearchReferral@hmhn.org",{"facility":93,"status":33,"city":94,"state":95,"zip":96,"country":37,"countryCode":38,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"University of Pennsylvania","Philadelphia","Pennsylvania","19104",{"type":40,"coordinates":98},[99,100],-75.16362,39.95238,{"lat":100,"lon":99},[103],{"name":104,"role":27,"phone":105,"phoneExt":19,"email":106},"Andrea Standish","215-662-2419","Andrea.Standish@Pennmedicine.upenn.edu",{"facility":32,"status":33,"city":94,"state":95,"zip":108,"country":37,"countryCode":38,"cosmosGeoPoint":109,"geoPoint":111,"contacts":112},"19107",{"type":40,"coordinates":110},[99,100],{"lat":100,"lon":99},[113],{"name":114,"role":27,"phone":115,"phoneExt":19,"email":116},"Ask Phase1","215-586-0199","AskPhase1@jefferson.edu",{"facility":32,"status":33,"city":118,"state":119,"zip":120,"country":37,"countryCode":38,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Nashville","Tennessee","37203",{"type":40,"coordinates":122},[123,124],-86.78444,36.16589,{"lat":124,"lon":123},[127],{"name":128,"role":27,"phone":129,"phoneExt":19,"email":19},"Sarah Cannon Research Institute","844-482-4812",{"facility":32,"status":33,"city":131,"state":132,"zip":133,"country":37,"countryCode":38,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"San Antonio","Texas","78229",{"type":40,"coordinates":135},[136,137],-98.49363,29.42412,{"lat":137,"lon":136},[140],{"name":141,"role":27,"phone":142,"phoneExt":19,"email":143},"Clinical Trial Navigator","210-580-9521","jgeorg@nextoncology.com",{"facility":32,"status":33,"city":131,"state":132,"zip":133,"country":37,"countryCode":38,"cosmosGeoPoint":145,"geoPoint":147,"contacts":148},{"type":40,"coordinates":146},[136,137],{"lat":137,"lon":136},[149,153],{"name":150,"role":27,"phone":151,"phoneExt":19,"email":152},"Isabel Jimenez","210-593-5265","isabel.jimenez@startresearch.com",{"name":154,"role":27,"phone":19,"phoneExt":155,"email":156},"Christina Santana","210-593-5205","csantana@startresearch.com",{"type":158,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100574188","phase-1-ct-95-in-advanced-cancers-associated-with-mesothelin-expression-100574188",false,"NCT06756035","CT-95 in Advanced Cancers Associated With Mesothelin Expression","Phase 1a\u002F1b Study of CT-95 in Advanced Cancers Associated With Mesothelin Expression","Inclusion Criteria:\n\n* ECOG 0 or 1\n* Subjects with evaluable disease per RECIST 1.1 or mRECIST\n* Subjects with adequate organ function.\n* Subjects with advanced cancers associated with mesothelin expression\n\nExclusion Criteria:\n\n* Uncontrolled significant active infection or any medical or other condition that in opinion of the investigator would preclude the subject's participation in the study.\n* Prior treatment with MSLN-targeted CD3 or chimeric antigen receptor T cell (CAR-T) therapy\n* Concurrent participation in another investigational clinical trial.\n* Evidence of leptomeningeal disease","ALL","18 Years",{"count":169,"type":170},70,"ESTIMATED","INTERVENTIONAL",[173],"PHASE1","This is a Phase 1a\u002F1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.",[176,177,178,179,180,181,182,183,184,185,186],"Mesothelin-Expressing Tumors","Epithelial Ovarian Cancer","Malignant Pleural Mesothelioma, Advanced","Malignant Peritoneal Mesothelioma, Advanced","Pancreatic Adenocarcinoma Advanced or Metastatic","Lung Adenocarcinoma Metastatic","Cholangiocarcinoma Advanced","Cholangiocarcinoma Non-resectable","Mesothelin-expressing Advanced Cancers","Mesothelin-positive Advanced Malignant Solid Tumors","Colorectal Cancer",[188,9,189,190,191],"Phase 1 Dose Escalation Study","Advanced, recurrent cancers","Unresectable, metastatic cancers","Cancers associated with mesothelin expression","2026-06-10",{"date":194,"type":195},"2026-06-12","ACTUAL",{"date":197,"type":195},"2025-03-31",{"date":199,"type":170},"2028-12",{"name":5,"class":6},9]